JNPMEDI
Category: AI in Healthcare
AI-based life science R&D platform company building an AI-native 'Clinical OS' that connects clinical trial data, documents, global regulatory information, and operations into a single environment. JNPMEDI was founded in 2020. The company is led by 정권호 (Kwunho Jeong). Based in Incheon (Songdo), South Korea. Team size: 101-500. Total funding raised: $12.6M. Latest round: Series B. Key investors include Pavilion Capital (Temasek), Naver, TBT Partners, Kakao Ventures, Murex Partners, AJU IB Investment, Gentium Partners, Torus Asset Management.
- Founded
- 2020
- Headquarters
- Incheon (Songdo), South Korea
- Team size
- 101-500
- Total funding
- $12.6M
Value proposition
Provides an end-to-end clinical trial operations and data management platform (Maven Clinical Cloud) plus professional services (CRO, regulatory, licensing) for pharma, biotech, and medical device companies, now evolving into an AI-centric Clinical OS that automates and connects the entire clinical trial lifecycle.
Products and solutions
Maven Clinical Cloud suite (Maven CDMS, Maven EDC, Maven Docs, Maven TMF, Maven Safety, Maven Builder, Maven Converter, Maven Coder Express, Maven VDR, Maven eRecruitment), AI-based Clinical OS (in development), Professional Services (CRO
Unique value
AI-native Clinical OS that integrates clinical data, documents, global regulatory guidelines, and operational workflows into one connected environment — moving beyond adding individual AI tools to existing systems toward a unified, AI-centric clinical trial operating system.
Target customer
Pharmaceutical, biotech, and medical device companies; Contract Research Organizations (CROs); digital therapeutics and digital medical device developers.
Industries served
Life sciences / clinical research, pharmaceuticals, biotech, medical devices, digital therapeutics, decentralized clinical trials (DCT).
Technology advantage
Proprietary Maven Clinical Cloud platform; CDISC Platinum membership; DTRA membership (first Korean member); AWS Managed Service Provider (MSP) and AWS Partner Software Path; ISO 27001/27799/27701 and ISO 13485 certifications; ~10 patents; AI document understanding/generation, anomaly/pattern analysis, and regulatory compliance verification.
How they differentiate
Differentiates by building an AI-native Clinical OS that unifies data, documents, regulatory, and operations into a single connected workflow, combined with an in-house CRO/professional services arm and an investment arm (JNPMEDI Partners) — an integrated RDC (Research, Development, Commercialization) model rather than a point-solution software vendor.
Main competitors
Medidata (Dassault Systèmes), Veeva Systems, IQVIA, Oracle Health Sciences, domestic: Central Bio (센트럴바이오), C&R Research (씨엔알리서치), Trial Informatics (트라이얼인포매틱스), MediHelpLine (메디헬프라인).
Key partnerships
Naver (strategic investment + AI/digital healthcare collaboration), AWS (MSP), Korea University Medical Center/Technology Holdings, Samsung Seoul Hospital, Inha University Hospital, DTRA, MCRA, IQVIA, Yonsei University BioHealth Technology Holdings, CMAX Clinical Research (Australia), Avance Clinical (Australia), ProSciento (US).
Notable customers
WELT-I insomnia DTx (DCT clinical trial), LSK Global PS, Samsung Seoul Hospital, Korea University Medical Center, various pharma/biotech and medical device clients.
Major milestones
Founded July 2020, TIPS selection (2022), Series A ₩14B led by Pavilion Capital (Nov 2022), WELT-I first Korean DCT digital therapeutic approval (2023), Scale-up TIPS (2023), Naver + TBT Partners strategic investment + AI collaboration (Aug 2025), Opened Singapore APAC HQ and US (Delaware) office (June 2026), Global TIPS ₩5B grant for AI Clinical OS (Aug 2026), Unicorn Bridge selection (2026), DIPS selection (2026).
Growth metrics
~153 employees (June 2026); 2024 revenue ~₩5.01B (~$3.7M) with operating loss ~₩6.56B; 10 patents; 592+ news mentions.
Market positioning
Leading Korean digital clinical trial platform company and early mover in decentralized clinical trials (DCT), expanding globally with strategic backing from Temasek's Pavilion Capital and Naver.
Geographic focus
South Korea (HQ Songdo/Incheon); APAC HQ in Singapore and North America office in Delaware (opened June 2026); expanding US, Australia, and global markets; partnerships with US (ProSciento, MCRA), Australia (CMAX, Avance), and Swiss (Basel University) entities.
Patents and IP
~10 patents (per THE VC); ISO 27001/27799/27701, ISO 13485 certifications; CDISC Platinum membership.
About 정권호 (Kwunho Jeong)
Ex-CSO at Dunamu's Lambda256; Team Leader BD & Strategy at Dunamu; Research Associate. Univ. of Washington Applied Physics BS.
Latest news about JNPMEDI
More AI in Healthcare companies
Official website: https://www.jnpmedi.com/
